false 0001847367 0001847367 2024-11-22 2024-11-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 22, 2024

 

 

 

Alumis Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-42143   86-1771129
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

280 East Grand Avenue

South San Francisco, California 94080

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (650) 231-6625

 

N/A

(Former name or former address, if changed since last report.)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)		   Name of each exchange
on which registered
Common Stock, $0.0001 par value per share   ALMS   The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 8.01 Other Events.

 

On November 22, 2024, revisions to estimates for primary completion and study completion dates related to Alumis Inc.’s (the “Company”) LUMUS clinical trial were made available on ClinicalTrials.gov. LUMUS is a global, multicenter, randomized, double-blind, placebo-controlled Phase 2 trial that is designed to evaluate the efficacy, safety and pharmacokinetics of multiple doses of ESK-001 in adult patients with systemic lupus erythematosus (SLE). This information, as updated, conforms with the Company’s disclosures in its filings with the Securities and Exchange Commission and previous public guidance. The Company explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Alumis Inc.
     
  By: /s/ Martin Babler
    Martin Babler
    President and Chief Executive Officer

 

Dated: November 25, 2024

 

 

v3.24.3
Cover
Nov. 22, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 22, 2024
Entity File Number 001-42143
Entity Registrant Name Alumis Inc.
Entity Central Index Key 0001847367
Entity Tax Identification Number 86-1771129
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 280 East Grand Avenue
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code 650
Local Phone Number 231-6625
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol ALMS
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Alumis (NASDAQ:ALMS)
Historical Stock Chart
Von Dez 2024 bis Jan 2025 Click Here for more Alumis Charts.
Alumis (NASDAQ:ALMS)
Historical Stock Chart
Von Jan 2024 bis Jan 2025 Click Here for more Alumis Charts.